Monopar Therapeutics (MNPR) Total Current Liabilities (2016 - 2026)

Monopar Therapeutics has reported Total Current Liabilities for 10 years, with the latest figure at $2.7 million in Q4 2025.

• Quarterly Total Current Liabilities fell 47.94% year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 million (down 47.94% YoY) and the FY2025 annual result came in at $2.7 million, down 47.94% from the prior year.
• Total Current Liabilities climbed to $2.7 million in Q4 2025 per MNPR's latest filing, from $2.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $5.3 million in Q4 2024 and troughed at $806272.0 in Q1 2021.
• A 5-year average of $2.3 million and a median of $2.1 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 198.98% in 2024, then sank 47.94% in 2025.
• Over 5 years, Total Current Liabilities stood at $1.6 million in 2021, then jumped by 97.96% to $3.1 million in 2022, then tumbled by 43.83% to $1.8 million in 2023, then soared by 198.98% to $5.3 million in 2024, then tumbled by 47.94% to $2.7 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.7 million, $2.6 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.